KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Other Gross PP&E Adjustments (2023 - 2025)

Biocryst Pharmaceuticals' Other Gross PP&E Adjustments history spans 8 years, with the latest figure at -$29.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 60.82% year-over-year to -$29.4 million; the TTM value through Dec 2025 reached -$29.4 million, down 60.82%, while the annual FY2025 figure was -$29.4 million, 60.82% down from the prior year.
  • Other Gross PP&E Adjustments reached -$29.4 million in Q4 2025 per BCRX's latest filing, down from -$7.7 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$6.9 million in Q2 2023 to a low of -$29.4 million in Q4 2025.
  • Average Other Gross PP&E Adjustments over 3 years is -$11.5 million, with a median of -$8.4 million recorded in 2024.
  • Peak YoY movement for Other Gross PP&E Adjustments: grew 26.74% in 2024, then plummeted 60.82% in 2025.
  • A 3-year view of Other Gross PP&E Adjustments shows it stood at -$15.7 million in 2023, then decreased by 16.79% to -$18.3 million in 2024, then tumbled by 60.82% to -$29.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Other Gross PP&E Adjustments are -$29.4 million (Q4 2025), -$7.7 million (Q3 2025), and -$7.9 million (Q2 2025).